MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/diseases6020035

Медицинская библиотека · Diseases (Basel, Switzerland) · 2018

Survival and Prognostic Factors in Mixed Cryoglobulinemia: Data from 246 Cases.

Mazzaro Cesare, Dal Maso Luigino, Mauro Endri, Gattei Valter, Ghersetti Michela, Bulian Pietro, Moratelli Giulia, Grassi Gabriele, Zorat Francesca, Pozzato Gabriele

СтатьяПеревод пока не подготовлен

Аннотация

INTRODUCTION

The clinical and therapeutic management of mixed cryoglobulinemia (MC) remains a subject of controversy. In addition, most studies have not recorded the long-term follow-up and the outcome of these cases.

MATERIAL AND

METHODS

We enrolled 246 patients affected by MC who were consecutively admitted to our Department from January 1993 to February 2013. Clinical and biological data had been recorded until June 2014.

RESULTS

The median age (at diagnosis) was 60 years (range 26⁻83). The aetiology was HCV in 95% of patients, HBV in 3% and &ldquo;essential&rdquo; in 2%. HCV genotype was 1b in 57%, genotypes 2⁻3 in 43%. MC was Type II in 203 of the cases (87%) and Type III in 52 (13%). The most frequent clinical manifestations were purpura (72%), chronic liver disease (70%), glomerulonephritis (35%), arthralgias (58%), peripheral neuropathy (21%), non-Hodgkin lymphoma (15%) and cutaneous ulcers (3%). Purpura, arthralgias, peripheral neuropathy, glomerulonephritis and non-Hodgkin lymphoma were more frequently observed in Type II than in Type III MC (p < 0.05). Treatments were interferon (IFN) or Pegilated-IFN (PEG-IFN) alone or plus Ribavirin (RIBA) in 101 cases, steroids with or without alkylating agents in 33 cases, Rituximab in 8 patients. The complete clinical, virological and immunological responses were associated with PEG-IFN plus RIBA. Severe infections were associated with renal failure. At 10 years, the overall survival rate was 71% in Type II MC and 84% in Type III (p < 0.053).

CONCLUSIONS

From our data, antiviral therapy is the first-line therapy in HCV-related MC, whereas steroids, alkylating agents and Rituximab should be considered as a second-line therapy. Given the heterogeneity of the disease, the role of these different therapeutic strategies should be checked in randomized controlled trials.

Для цитирования: Mazzaro Cesare, Dal Maso Luigino, Mauro Endri, Gattei Valter, Ghersetti Michela, Bulian Pietro, Moratelli Giulia, Grassi Gabriele, Zorat Francesca, Pozzato Gabriele. Survival and Prognostic Factors in Mixed Cryoglobulinemia: Data from 246 Cases.. Diseases (Basel, Switzerland). 2018. DOI: 10.3390/diseases6020035.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.